Probes: ROS1 (6q22.1)
Disease(s): Non-small cell lung carcinoma (NSCLC)
ROS1 gene rearrangements are found in 1-2% of non-small cell lung carcinoma (NSCLC). Pre-clinical and early clinical evidence suggests ROS1-rearranged tumors may be sensitive to the dual ALK/MET inhibitor crizotinib.
- Paraffin Block: Send paraffin block. Also send circled H&E slide for tech-only (required).
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.